The role of ubiquitin C–terminal hydrolase (UCH‐L1) and protein S100B in differentiating patients with epileptic and psychogenic non‐epileptic seizures – Pilot study
Epilepsia Open · 2025
DOI: 10.1002/epi4.13130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia Open, 2025. Verfasst von Biljana Dapic Ivancic und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Centre Zagreb, Zagreb, Croatia. Hauptthemen laut MEDLINE: S100 Calcium Binding Protein beta Subunit, Ubiquitin Thiolesterase, Seizures, Epilepsy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University grants for financing of scientific and artistic activities University of Zagreb, Croatian society for affective disorders of the Croatian Medical Association.
Abstract (Originalsprache)
Objective
Psychogenic non‐epileptic seizures (PNES) are functional neurological disorders that are often misdiagnosed and treated as epileptic seizures (ES). Video‐electroencephalography (v‐EEG) is the gold standard for differentiating ES from PNES. However, blood biomarkers provide a faster and more accessible methodology, particularly for unwitnessed events. Ubiquitin C‐terminal hydrolase L1 (UCH‐L1) and protein S100B are key biomarkers released following neuronal and glial damage. Previous experimental and clinical studies have shown increased postictal serum and cerebrospinal fluid (CSF) levels of UCH‐L1 and S100B in patients with ES.
Methods
This prospective cohort pilot study compared postictal serum levels of UCH‐L1 and S100B proteins in subjects with ES to those with PNES, aiming to identify specific biomarkers for distinguishing these conditions. To exclude confounding factors, the inclusion criteria required normal magnetic resonance (MR) findings of the brain. Strict timing of blood sampling and v‐EEG monitoring were used for diagnosing PNES. The study included 32 subjects with epilepsy, 36 with PNES, and 30 healthy controls.
Results
A significant difference in postictal UCH‐L1 levels was observed among the groups. Subjects with ES had significantly higher postictal UCH‐L1 levels (pg/mL) compared to those with PNES ( p = 0.049) and healthy controls ( p = 0.029). No significant differences were found between PNES subjects and healthy controls ( p = 0.756). Postictal protein S100B levels did not differ significantly between the groups ( p = 0.515). Significance This study confirms the potential of postictal UCH‐L1 levels as a biomarker for distinguishing ES from PNES. However, it also raises questions about the utility of protein S100B as a biomarker in epilepsy. Given the pilot nature of this study, UCH‐L1 cannot yet be adopted for clinical use due to the small sample size, as statistical significance may have been driven by a subset of eight patients. Plain Language Summary This study evaluated two potential biomarkers, UCH‐L1 and S100B, to differentiate ES from PNES in clinical practice. Our findings showed elevated postictal UCH‐L1 levels in subjects with epilepsy compared to those with PNES, while no significant differences in S100B levels were observed among the groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospital Centre Zagreb, Zagreb, Croatia.
- Referral Centre of the Ministry of Health of the Republic of Croatia for Epilepsy (Affiliated Member of the ERN EpiCARE), Zagreb, Croatia.
- School of Medicine, University of Zagreb, Zagreb, Croatia.
- Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia.
- Department for Psychiatry and Psychological Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.
ORCID-Profile: Biljana Dapic Ivancic
Förderung
- University grants for financing of scientific and artistic activities University of Zagreb
- Croatian society for affective disorders of the Croatian Medical Association
Zitieren
APA
Dapic Ivancic, B., Petelin Gadze, Z., Ganoci, L., Nimac Kozina, P., Rogic, D., & Zivkovic, M. (2025). The role of ubiquitin C–terminal hydrolase (UCH‐L1) and protein S100B in differentiating patients with epileptic and psychogenic non‐epileptic seizures – Pilot study. Epilepsia Open. https://doi.org/10.1002/epi4.13130
Vancouver
Dapic Ivancic B, Petelin Gadze Z, Ganoci L, Nimac Kozina P, Rogic D, Zivkovic M. The role of ubiquitin C–terminal hydrolase (UCH‐L1) and protein S100B in differentiating patients with epileptic and psychogenic non‐epileptic seizures – Pilot study. Epilepsia Open. 2025. doi:10.1002/epi4.13130
BibTeX
@article{DapicIvancic2025,
author = {Dapic Ivancic, Biljana and Petelin Gadze, Zeljka and Ganoci, Lana and Nimac Kozina, Petra and Rogic, Dunja and Zivkovic, Maja},
title = {The role of ubiquitin C–terminal hydrolase (UCH‐L1) and protein S100B in differentiating patients with epileptic and psychogenic non‐epileptic seizures – Pilot study},
journal = {Epilepsia Open},
year = {2025},
doi = {10.1002/epi4.13130}
}
EUVIMED